|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���������� |
|
�����Ʒ� |
| ��������������� | |
|
������ |
|
֣�� |
| PubMed | |
|
Article by |
|
Article by |
�������߲�������ѧ���ƽ�չ
������, ֣��
�㽭��ѧҽѧԺ�����ڶ�ҽԺƤ����, ����310009
�������߲�����������ϵͳ�������Ҳ�����Ӧ����,���°����ٻ��ϵͳ����,�ٴ����ֲ�һ��һ�鼲���������������ʵ͡��²к������ʸ�,�������ܵ����ӡ������������߲�������,Ŀǰ����ʮ����������ķ���,���������������ѧ���ƴ������µ�ϣ����Ϊ��,��Ҫ�������������߲�������ϵͳ�Ժ���Ǵ������ʪ�ؽ�������ѧ���ƽ�չ��
[2] Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes. Immunol Today, 1994, 15:450-454.
[3] Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.Rheumatology (Oxford), 2001, 40:205-211.
[4] Cambridge G, Leandro MJ, Edwards JCW, et al. B lymphocyte depletion in patients with rheumatoid arthritis:serial studies of immunological parameters. Arthritis Rheum, 2002, 46(Suppl 9):S1350.
[5] Stahl HD, Szczepanski L, Szechinski J, et al. Rituximab in RA:efficacy and safety from a randomized controlled trial. Ann Rheum Dis,2003,62(Suppl 1):OP004.
[6] Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody:a randomized,placebo-controlled trial in patients with rheumatoid arthritis. Arthritis Rheum, 2002, 46(Suppl 9):S446.
[7] Rathmell JC, Fournier S, Weintraub BC, et al. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4+ T cells. J Exp Med, 1998, 188:651-659.
[8] Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaR��a genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum,2003, 48(2):455-459.
[9] Leandro M J, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum, 2002, 46:2673-2677.
[10] Anolik JH, Campbell D, Felgar RE, et al. B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum,2002, 46(Suppl 9):S717.
[11] Tokano Y, Morimoto S, Kaneko H,et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines. Clin Exp Immunol, 1999, 116:169-173.
[12] Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. Pharmacol Rev, 2003, 55:241-269.
[13] Aringer M, Stummvoll GH, Steiner G,et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford),2001, 40:876-881.
[14] Aringer M, Zimmermann C, Graninger WB, et al. TNF is an essential mediator in lupus nephritis. Arthritis Rheum, 2002, 46:3418.
[15] Su X, Zhou T, Yang P, et al. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.Arthritis Rheum, 1998, 41:139-149.
[16] Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus:a rationale for therapeutic intervention. Lupus, 2004, 13:344-347.
[17] Kiberd BA, Stadnyk AW. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology, 1995, 30:131.
[18] Herrera-Esparza R,Barbosa-Cisneros O,Villalobos-Hurtado R,et al.Renal Expression of Il-6 and TNF�� genes in lupus nephritis. Lupus,1998, 7:154-158.
[19] Bossu P, Neumann D, Del Giudice E,et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.Proc Natl Acad Sci U S A, 2003, 100:14181-14186.